This article is a commentary on:
Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
Uffe Ravnskov
Kilmer S. McCully- 1Independent Researcher, Lund, Sweden
- 2Pathology and Laboratory Medicine Service, Veterans Affairs Boston Healthcare System, Boston, MA, United States
A Commentary on:
Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
By Deng C-F, Zhu N, Zhao T-J, Li H-F, Gu J, Liao D-F and Qin L (2022). Front. Oncol. 12:803473. doi: 10.3389/fonc.2022.803473
Introduction
As demonstrated by Deng et al. (1), the association between cancer and LDL-cholesterol is an utterly complicated issue. Many studies have shown that high LDL-C is associated with cancer, whereas other studies have found the opposite. In a previous review (2) we have shown that one of the causes of the conflicting findings is that few have realized that the lipoproteins participate in the immune system by adhering to and inactivating almost all types of microorganisms and their toxic products (3) and that 15–20% of human cancers may have a viral or bacterial etiology (4). However, as metastasing cancer cells need much cholesterol, its lowering may perhaps be beneficial in patients with advanced cancer.
Low Cholesterol May Cause Cancer
Several cohort studies have found that cancer patients have low cholesterol. A common explanation is that cancer cells need cholesterol. However, in nine studies the authors had followed more than 140,000 individuals for 10 - >30 years. After having excluded patients who suffered from cancer during the first four years, they found that cancer appearing during the observation period was inversely associated with cholesterol measured at the start (2). Furthermore, at least five cholesterol-lowering trials have resulted in cancer (5–9). In 4S and HPS (5, 6), the differences between the treatment and the control groups were insignificant, but they become significant if the two trials are calculated together (2). At least four case-control studies have shown that cancer patients have been treated more often with statins than controls. In one of them, almost twice as many patients with lymphoid malignancies had been treated with statins (10). In the other three, which included 2650 patients with prostate cancer, the cancer patients had been treated significantly more often with statins (11–13). Furthermore, in a study of 83 patients with bladder cancer, the tumor became more aggressive in 53% of those who took statins but only in 18% of the non-users (14). These findings contradict the idea that the association between statin treatment and low cholesterol is due to liver damage.
Animal experiments are in accord as well. In a review of data from preclinical studies with lipid-lowering drugs, Newman and Hulley concluded that these drugs produced cancer in rodents after a short time at serum levels close to those achieved in clinical trials (15).
When microorganisms are covered with LDL, they are taken up by macrophages (2), and as macrophages kill the microorganisms by oxidation, it is obvious that LDL may become oxidized as well. The association between cancer and ox-LDL may therefore be caused by infections with carcinogenic microorganisms.
Discussion
Many follow-up studies and trials have shown that statin-users suffer less often from cancer than non-users. However, several studies have shown that 40-90 per cent of statin-treated patients stop taking their medication after a year or two (16). As most patients who are prescribed cholesterol-lowering treatment have high LDL-C whereas most of the non-treated controls have normal or low LDL-C, it is impossible to know whether the better outcome in these follow-up studies was due to statin treatment or to the patient’s high LDL-C, because none of these studies have asked the patients whether they have continued their statin treatment.
Another bias was presented by Agnoli et al. (17). They followed a large number of hospital patients in Italy between 1993 and 2008 after having measured their lipid values and found that LDL-C at the start was associated with the number who suffered from colon cancer during the observation period. As statin treatment was introduced in the early nineties, many among those with the highest values must have been prescribed such treatment. It is therefore impossible to know whether their cancer was caused by their abnormal lipid values or by statin treatment A more accurate appraisal is therefore to relate the number of cancer cases to the achieved blood cholesterol concentration, as in the study by Matsuzaki et al. (18). They followed 47 294 hypercholesterolemic patients on a low dose simvastatin. Six years later, the number of cancer deaths was more than three times higher among those whose total cholesterol was <160 mg/dl compared with those whose cholesterol was normal or high. A better method is also to measure the lipids at the time of diagnosis as performed by Garrido et al. They measured the lipids of 237 patients remitted for prostate biopsy. About half of them had prostate cancer and their LDL-C was significantly lower than that of those without cancer. However, the finding was not adjusted for other risk factors
According to a meta-analysis of 26 statin trials by the Cholesterol Treatment Trialists’ Collaboration (19), cancer was not seen significantly more often in the treatment groups. However, almost all statin trials have lasted only five years or less, and except for breast cancer, non-melanoma skin cancer and prostate cancer, it takes a much longer time before exposure to carcinogenic chemicals results in easily diagnosed cancers. For instance, it may take several decades before smoking results in bronchial cancer.
Furthermore, most trials did not record non-melanoma skin cancer, the cancer type that is most easy to diagnose. However, in three of the trials mentioned above where statin treatment resulted in cancer, the type of cancer was mentioned. In two of them it was non-melanoma skin cancer (5, 6) and in one of them it was breast cancer (7). In accordance, the number of non-melanoma skin cancer in USA increased dramatically after the introduction of the statins (20).
A possibility is that cholesterol-lowering may protect against metastases. In the CARE trial (7), significantly more women in the treatment group suffered from breast cancer, but in a recent study, 360 women with breast cancer were followed for 23 years (21). After exclusion of those with prediagnostic statin use and those with breast cancer in situ, those who had been prescribed statin treatment during the observation period suffered less often from breast cancer recurrence and lived longer than the untreated. Unfortunately, the authors did not examine whether those on statin treatment had continued the treatment.
A theoretical explanation of the pro-carcinogenic effect of low blood cholesterol is the mitochondrial dysfunction and toxicity caused by loss of thioretinaco ozonide, the active site of oxidative phosphorylation, from the mitochondrial permeability transition pore, the opening of which is inhibited by cholesterol (22, 23).
We think that the benefit of cholesterol-lowering treatment is questionable because this treatment may cause many other serious side effects (24), and most of 38 follow-up studies of patients and healthy people have shown that those with high LDL-C live just as long or longer than people with normal or low LDL-C; none of them found the opposite (25, 26)). It is possible that statin treatment may inhibit the growth of metastases, but this issue requires further investigation.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Deng C, Zhu N, Zhao T, Li H, Gu J, Liao D, et al. Involvement of LDL and Ox-LDL in Cancer Development and Its Therapeutical Potential. Front Oncol (2022) 12:803473. doi: 10.3389/fonc.2022.803473
2. Ravnskov U, McCully KS, Rosch PJ. The Statin-Low Cholesterol-Cancer Conundrum. QJM (2012) 105(4):383–8. doi: 10.1093/qjmed/hcr243
3. Ravnskov U, McCully KS. Vulnerable Plaque Formation From Obstruction of Vasa Vasorum by Homocysteinylated and Oxidized Lipoprotein Aggregates Complexed With Microbial Remnants and LDL Autoantibodies. Ann Clin Lab Sci (2009) 39(1):3–16.
4. Burnett-Hartman AN, Newcomb PA, Potter JD. Infectious Agents and Colorectal Cancer: A Review of Helicobacter Pylori, Streptococcus Bovis, JC Virus, and Human Papillomavirus. Cancer Epidemiol Biomark Prev (2008) 17(11):2970–9. doi: 10.1158/1055-9965.EPI-08-0571
5. Randomised Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4s). Lancet (1994) 344(8934):1383–9.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Lancet (2002) 360(9326):7–22. doi: 10.1016/S0140-6736(02)09327-3
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med (1996) 334(14):1001–9. doi: 10.1056/NEJM19961003335401
8. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomised Controlled Trial. Lancet (2002) 360(9346):1623–30. doi: 10.1016/s0140-6736(02)11600-x
9. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med (2008) 359(13):1343–56. doi: 10.1056/NEJMoa0804602
10. Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, et al. Use of Hydroxy-Methyl-Glutaryl Coenzyme A Reductase Inhibitors is Associated With Risk of Lymphoid Malignancies. Cancer Sci (2006) 97(2):133–8. doi: 10.1111/j.1349-7006.2006.00153.x
11. Chang CC, Ho SC, Chiu HF, Yang CY. Statins Increase the Risk of Prostate Cancer: A Population-Based Case-Control Study. Prostate (2011) 71(16):1818–24. doi: 10.1002/pros.21401
12. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin Use and Risk of Prostate Cancer: Results From a Population-Based Epidemiologic Study. Am J Epidemiol (2008) 168(3):250–60. doi: 10.1093/aje/kwn141
13. Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM. Effect of Statin Use on Biochemical Outcome Following Radical Prostatectomy. BJU Int (2011) 108(8 Pt 2):E211–6. doi: 10.1111/j.1464-410X.2011.10159.x
14. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of Statins and Outcome of BCG Treatment for Bladder Cancer. N Engl J Med (2006) 355(25):2705–7. doi: 10.1056/NEJMc062714
15. Newman TB, Hulley SB. Carcinogenicity of Lipid-Lowering Drugs. JAMA (1996) 275(1):55–60. doi: 10.1001/jama.1996.03530250059028
16. Diamond DM, de Lorgeril M, Kendrick M, Ravnskov U, Rosch PJ. Formal Comment on “Systematic Review of the Predictors of Statin Adherence for the Primary Prevention of Cardiovascular Disease”. PloS One (2019) 14(1):e0205138. doi: 10.1371/journal.pone.0205138
17. Agnoli C, Grioni S, Sieri S, Sacerdote C, Vineis P, Tumino R, et al. Colorectal Cancer Risk and Dyslipidemia: A Case–Cohort Study Nested in an Italian Multicentre Cohort. Cancer Epidemiol (2014) 38(2):144–51. doi: 10.1016/j.canep.2014.02.002
18. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia. Circ J (2002) 66(12):1087–95. doi: 10.1253/circj.66.1087
19. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data From 170,000 Participants in 26 Randomised Trials. Lancet (2010) 376(9753):1670–81. doi: 10.1016/S0140-6736(10)61350-5
20. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006. Arch Dermatol (2010) 146(3):283–7. doi: 10.1001/archdermatol.2010.19
21. Inasu M, Feldt M, Jernström H, Borgquist S, Harborg S. Statin Use and Patterns of Breast Cancer Recurrence in the Malmö Diet and Cancer Study. Breast (2022) 61:123–8. doi: 10.1016/j.breast.2022.01.003
22. McCully KS. Loss of the Thioretinaco Ozonide Oxygen Adenosine Triphosphate Complex From Mitochondria Produces Mitochondrial Dysfunction and Carcinogenesis. Ann Clin Lab Sci (2018) 48(3):386–93.
23. McCully KS. Chemical Pathology of Homocysteine VII. Cholesterol, Thioretinaco Ozonide, Mitochondrial Dysfunction, and Prevention of Mortality. Ann Clin Lab Sci (2019) 49(4):55–68.
24. Diamond DM, Ravnskov U. How Statistical Deception Created the Appearance That Statins Are Safe and Effective in Primary and Secondary Prevention of Cardiovascular Disease. Exp Rev Clin Pharmacol (2015) 8(2):201–10. doi: 10.1586/17512433.2015.1012494
25. Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Harcombe Z, et al. Lack of an Association or an Inverse Association Between Low-Density Lipoprotein Cholesterol and Mortality in the Elderly: A Systematic Review. BMJ Open (2016) 6(6):e010401. doi: 10.1136/bmjopen-2015-010401
Keywords: cancer, LDL-cholesterol, ox-LDL, lipid-lowering treatment, microorganisms, immune system
Citation: Ravnskov U and McCully KS (2022) Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential. Front. Oncol. 12:891352. doi: 10.3389/fonc.2022.891352
Received: 07 March 2022; Accepted: 06 April 2022;
Published: 02 May 2022.
Edited by:
Xiang-Xi Mike Xu, University of Miami, United StatesReviewed by:
Wensi Tao, University of Miami Health System, United StatesCopyright © 2022 Ravnskov and McCully. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Uffe Ravnskov, uravnskov@gmail.com